Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

November 30, 2012

Study Completion Date

December 31, 2012

Conditions
Brain Metastases
Interventions
DRUG

Bendamustine

Approximately 15-24 study patients will be enrolled in this Phase I trial. Study patients will receive a weekly dose of IV bendamustine with whole brain radiation therapy for 3 weeks and then receive a fourth dose of IV bendamustine one week after completion of whole brain radiation therapy. The first dose of IV bendamustine will be given when whole brain radiation is initiated.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

collaborator

Cephalon

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER